Trial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline CST with statistical ...

Data from the Phase 4 observational real-world safety study of the intravitreal implant were presented at the annual American Academy of Ophthalmology (AAO) conference. ATLANTA, Oct. 06, 2022 (GLOBE ...

Data highlight ILUVIEN’s advantages as the only therapy that consistently treats diabetic macular edema (DME) for up to 3 years ATLANTA, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc.

To report the 12-months visual and anatomical outcomes of chronic diabetic macular oedema (DMO) treated with ILUVIEN in a real-world clinical practice in a single tertiary referral centre.

ATLANTA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned ...

Alimera Sciences, Inc., (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced ...

ASMR level IV opinion is significant step towards commercialization in France of the first and only treatment approved for chronic diabetic macular edema ATLANTA, July 24, 2013 /PRNewswire/ -- Alimera ...

Alimera Sciences Limited, the European subsidiary of Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of ...

We report the clinical efficacy and safety of intravitreal Iluvien implant in vitrectomised eyes of chronic diabetic macular oedema (DMO), irrespective of the timing of vitrectomy procedure. Case 1 A ...

Please provide your email address to receive an email when new articles are posted on . Iluvien is now indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment. ANI ...

Please provide your email address to receive an email when new articles are posted on . Alimera Sciences has initiated enrollment for its prospective Iluvien study New Day, according to a press ...

ATLANTA, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned ...